Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107913
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2005-04-11
Brief Title:
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Sponsor:
Hematology and Oncology Specialists
Organization:
Hematology and Oncology Specialists
Study Overview
Official Title:
Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Status:
UNKNOWN
Status Verified Date:
2005-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP Idiopathic Thrombocytopenic Purpura
Detailed Description:
Eligible patients will receive Doxil 20 mgm2 IV over 1 hour every 2 weeks Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None